Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | JAK1 | P23458 | 5/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29513749 | 1.00 | GSK3B (0.56) | GSK3BGSK3AMAPK14JAK1JAK2 | |
| SCHEMBL25347311 | 0.89 | GSK3B (0.48) | GSK3BGSK3AMAPK14JAK1JAK2 | |
| SCHEMBL29514309 | 0.89 | GSK3B (0.48) | GSK3BGSK3AMAPK14JAK1JAK2 | |
| SCHEMBL29513809 | 0.87 | MAP4K1 (0.44) | GSK3BGSK3AMAPK14ABL1 | |
| SCHEMBL25346743 | 0.87 | MAP4K1 (0.44) | GSK3BGSK3AMAPK14ABL1 | |
| SCHEMBL29513655 | 0.87 | MAP4K1 (0.44) | GSK3BGSK3AMAPK14ABL1 | |
| SCHEMBL25347848 | 0.87 | MAP4K1 (0.44) | GSK3BGSK3AMAPK14ABL1 | |
| SCHEMBL25346233 | 0.86 | GSK3B (0.43) | GSK3BGSK3AMAPK14JAK1ABL1 | |
| SCHEMBL29513718 | 0.86 | GSK3B (0.43) | GSK3BGSK3AMAPK14JAK1ABL1 | |
| SCHEMBL25346785 | 0.86 | LMNA (0.42) | GSK3BGSK3AMAPK14JAK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4225741-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116438182-A | 7-azaindole compounds for inhibiting BCR-ABL tyrosine kinase | 活力疗法公司 | 2023-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | GSK3B 669/4885GSK3A 670/4885MAPK14 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.